当前位置: 首页 > 详情页

The effect of remote ischemic conditioning combined with tirofiban on early neurological deterioration in small artery occlusive stroke

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China [2]Beijing Geriatr Hosp, Dept Neurol, Beijing, Peoples R China
出处:
ISSN:

关键词: Remote ischemic conditioning Early neurological deterioration Small artery occlusive Stroke Tirofiban

摘要:
ObjectivesEarly neurological deterioration (END) remains a significant challenge in the treatment of small artery occlusive (SAO) stroke. The purpose of this study was to evaluate the efficacy and safety of remote ischemic conditioning (RIC) combined with tirofiban for patients with SAO stroke experiencing END.MethodsWe retrospectively reviewed 143 consecutive patients with acute SAO stroke experiencing END who received intravenous tirofiban between January 2021 and December 2024. According to the use of RIC treatment, the patients were divided into RIC group (72 cases) and control (no-RIC) group (71 cases). The primary efficacy outcome was early neurological improvement (a decrease of >= 2 points in the National Institutes of Health Stroke Scale (NIHSS) score at 7 days after END). The secondary efficacy outcomes included absolute reduction in NIHSS score at 7 days, modified Rankin Scale scores at 90 days, proportion of disabling stroke, recurrence of ischemic stroke within 90 days. The safety outcomes were symptomatic intracranial hemorrhage, any ICH, adverse events, and 90-day all-cause mortality.ResultsThe RIC group exhibited a greater absolute reduction in NIHSS score at 7 days after treatment (mean +/- SD: 1.67 +/- 1.80 vs. 0.96 +/- 1.91; adjusted P=0.015), and early neurological improvement was achieved in 55.6% of the RIC group and 29.6% of the control group (adjusted odds ratio, 3.34 [95% CI, 1.61-6.93]; P=0.001). No symptomatic intracranial hemorrhage or any intracranial hemorrhage occurred in either group. Additionally, the 90-day all-cause mortality did not differ significantly between the RIC and sham groups (1.4% vs. 2.8%, hazard ratio, 0.49 [95% CI, 0.04-5.41]; P=0.561).ConclusionsIn patients with small artery occlusive stroke experiencing END, the combination of RIC and tirofiban seems associated with early neurological improvement without increasing the risk of intracranial hemorrhage or serious adverse events. Future multicenter, large-sample randomized clinical trials are warranted to validate these results.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 3 区 医学
小类 | 4 区 临床神经病学
最新[2025]版:
大类 | 3 区 医学
小类 | 4 区 临床神经病学
JCR分区:
出版当年[2023]版:
Q3 CLINICAL NEUROLOGY
最新[2024]版:
Q3 CLINICAL NEUROLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者:
第一作者机构: [1]Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China [2]Beijing Geriatr Hosp, Dept Neurol, Beijing, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:18307 今日访问量:1 总访问量:1007 更新日期:2025-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院